DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Temovate (Clobetasol Propionate Topical) - Summary

 
 



TEMOVATE SUMMARY

TEMOVATE (clobetasol propionate emollient cream)
Emollient, 0.05%

TEMOVATE (clobetasol propionate cream and ointment) Cream and Ointment contain the active compound clobetasol propionate, a synthetic corticosteroid, for topical dermatologic use. Clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity.

TEMOVATE Cream and Ointment are super-high potency corticosteroid formulations indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Use in pediatric patients under 12 years of age is not recommended.

As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.


See all Temovate indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Temovate (Clobetasol Topical)

Positive results from Phase 2b study of dupilumab in patients with moderate-to-severe atopic dermatitis announced
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.07.11]
Sanofi and Regeneron Pharmaceuticals, Inc. have announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe...

Atopic Dermatitis
Source: MedicineNet Genetic Disease Specialty [2014.04.23]
Title: Atopic Dermatitis
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 4/23/2014 12:00:00 AM

Atopic Eczema (Atopic Dermatitis) Quiz: Test Your Skin Disorders IQ
Source: MedicineNet hydroxyzine Specialty [2013.12.20]
Title: Atopic Eczema (Atopic Dermatitis) Quiz: Test Your Skin Disorders IQ
Category: MedicineNet Quiz
Created: 3/20/2012 12:50:00 PM
Last Editorial Review: 12/20/2013 12:24:14 PM

Eczema (Atopic Dermatitis) Pictures Slideshow: Causes, Symptoms and Treatment
Source: MedicineNet Skin Test For Allergy Specialty [2013.12.18]
Title: Eczema (Atopic Dermatitis) Pictures Slideshow: Causes, Symptoms and Treatment
Category: Slideshows
Created: 3/26/2012 12:00:00 AM
Last Editorial Review: 12/18/2013 12:00:00 AM

Seborrheic Dermatitis
Source: MedicineNet ciclopirox Specialty [2012.03.16]
Title: Seborrheic Dermatitis
Category: Diseases and Conditions
Created: 3/16/2012 5:47:00 PM
Last Editorial Review: 3/16/2012 5:47:54 PM

more news >>

Published Studies Related to Temovate (Clobetasol Topical)

A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index. [2012]
CONCLUSION: The present study proved the efficacy of twice-daily tacrolimus and

A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0.1% vs. clobetasol propionate 0.05% in childhood vitiligo. [2011.09]
BACKGROUND: Both clobetasol propionate 0.05% (CP 0.05%) and tacrolimus 0.1% (T 0.1%) ointments have been shown to be efficacious and safe in treating vitiligo in the paediatric population. OBJECTIVES: To assess efficacy and safety of these two therapies compared with each other and with placebo... CONCLUSIONS: Both CP 0.05% and T 0.1% ointments offer similar benefit in paediatric vitiligo, both facial and nonfacial. The facial lesions responded faster than the nonfacial ones. (c) 2011 The Authors. BJD (c) 2011 British Association of Dermatologists.

Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial. [2011.08]
BACKGROUND: Clobetasol propionate 0.05% spray is available for treating moderate-to-severe plaque psoriasis; however, there is limited information with plaque psoriasis of the scalp. OBJECTIVE: Evaluate the efficacy, safety, and quality-of-life impact of clobetasol propionate 0.05% spray in patients with moderate to severe plaque psoriasis of the scalp... CONCLUSION: Treatment with clobetasol propionate 0.05% spray for up to four weeks is effective and well tolerated for moderate-to-severe plaque psoriasis of the scalp.

Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet A therapy in palmoplantar psoriasis. [2011.08]
AIM: Palmoplantar psoriasis (PPP) produces significant morbidity and requires prompt treatment. Topical agents form the mainstay of therapy. We compared the efficacy and side-effect profile of a steroid/coal-tar combination with topical psoralen and solar ultraviolet A (PUVAsol) in PPP... CONCLUSION: Both treatments had comparable efficacy. In both groups, patients experienced 'good improvement' after 16 weeks of therapy. (c) The Author(s). CED (c) 2011 British Association of Dermatologists.

Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0.05% combined with ketoconazole shampoo 2%: a randomized, controlled study. [2011.07]
BACKGROUND: Topical antifungals and corticosteroids are the mainstay of treatment for seborrhoeic dermatitis. The short-contact clobetasol propionate 0.05% shampoo (CP) is an efficacious and safe once-daily treatment for scalp psoriasis. OBJECTIVES: To evaluate the efficacy and safety of CP alone and combined with ketoconazole shampoo 2% (KC) in the treatment of moderate to severe scalp seborrhoeic dermatitis... CONCLUSIONS: The combination therapy of twice-weekly CP alternating with twice-weekly KC provided significantly greater efficacy than KC alone and a sustained effect in the treatment of moderate to severe scalp seborrhoeic dermatitis. (c) 2011 The Authors. BJD (c) 2011 British Association of Dermatologists 2011.

more studies >>

Clinical Trials Related to Temovate (Clobetasol Topical)

A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam [Completed]

Clobetasol for Oral Graft-Versus-Host Disease [Recruiting]
Background:

- Oral graft-versus-host disease (GVHD) is a possible complication of bone marrow

transplants. It is the result of the donor cells trying to attack the recipient's body. Symptoms include dry mouth, sensitivity and pain when tasting certain spices and flavors, and painful swallowing. Steroids are a possible effective treatment for GHVD, but they can cause side effects when given as pills or injections. Steroids given in a cream or rinse form, applied directly to the site of the symptoms, can have fewer side effects. However, their effectiveness as a rinse has not been tested in the mouth. Researchers want to see if a steroid called clobetasol can be used as a mouth rinse to treat oral GHVD.

Objectives:

- To see if a clobetasol rinse is a safe and effective treatment for oral graft-versus-host

disease.

Eligibility:

- Individuals at least 12 years of age who have oral GHVD and are not allergic to

clobetasol.

Design:

- Participants will be screened with a physical exam and medical history. Blood and urine

samples will be collected. They will also have an oral exam, a mouth tissue biopsy, and other tests before starting the study drug.

- Participants will be separated into two groups. One group will receive clobetasol; the

other will have a placebo liquid.

- Participants will rinse their mouths with the study liquid three times a day after

meals for 2 weeks.

- After 2 weeks, participants will have another study visit with blood tests and other

exams.

- After the study visit, all participants will start to use the clobetasol rinse. Those

who originally had clobetasol will use the rinse for another 2 weeks. Those who originally had a placebo will use the rinse for 4 weeks.

- Participants will have a follow-up exam after the end of treatment.

Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis [Recruiting]
This is a 12-week, open-label, pilot trial evaluating the efficacy and safety of the combination of Clobex® spray with excimer laser therapy as the initial treatment of generalized plaque psoriasis, followed by maintenance therapy with topical Vectical. The study will be conducted in three distinct periods, namely Period A, Period B, and Period C, each of 4 weeks duration. During Period A (weeks 1 through 4), patients will use Clobex® spray twice daily along with excimer laser treatments twice weekly with the Photomedex XTRAC® Velocity machine. The goal of Period A is to achieve PASI 75 in 100% of patients within four weeks. During Period B (weeks 5 through 8), patients would be treated with topical Vectical® twice daily. Thus, there is a steroid-free interval during which patients will not be using Clobex® spray. The goal of Period B is to maintain the patient's response using only non-steroid options. During Period C of the study, patients will use Clobex® spray BID and Vectical® BID. Period C (weeks 9 through 12) will be a "booster" period in which the goal is to see if 100% of patients can achieve PASI 90-100. Regarding excimer laser therapy: all patients will be receiving excimer laser therapy twice weekly for the first 6 weeks of the study (up to the halfway point) which is 12 excimer laser treatments. At that point, only those patients achieving Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis [Completed]
Evaluation of the effectiveness of Clobex® Spray, 0. 05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents.

Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy [Recruiting]
The purpose of this study is to determine whether spironolactone could significantly reduce cutaneous atrophy due to corticosteroids.

more trials >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 2 ratings/reviews, Temovate has an overall score of 7. The effectiveness score is 6 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
 

Temovate review by 46 year old female patient

  Rating
Overall rating:  
Effectiveness:   Moderately Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   dyshidrosis
Dosage & duration:   twice daily (dosage frequency: twice daily) for the period of two weeks
Other conditions:   noce
Other drugs taken:   None
  
Reported Results
Benefits:   The resulting small, fluid-filled blisters (vesicles) most commonly occur on the palms and fingers of your hands and on the soles and toes of your feet. The blisters usually last for three to four weeks. The blisters often cause intense itching. Scratching the blisters can damage the skin and, in some cases, lead to infection. Once the blisters dry, they often leave cracks and painful grooves (fissures) in your skin. Risk factors Dyshidrosis occurs twice as often in women as in men. Other risk factors include: * Stress, because dyshidrosis appears to be more common during times of stress * Exposure to metal salts, such as chromium, cobalt and nickel — usually through cement or mechanical work * Having seasonal allergies, such as hay fever * Frequently exposing your skin to water or other wet substances
Side effects:   The resulting small, fluid-filled blisters (vesicles) most commonly occur on the palms and fingers of your hands and on the soles and toes of your feet. The blisters usually last for three to four weeks. The blisters often cause intense itching. Scratching the blisters can damage the skin and, in some cases, lead to infection. Once the blisters dry, they often leave cracks and painful grooves (fissures) in your skin. Risk factors Dyshidrosis occurs twice as often in women as in men. Other risk factors include: * Stress, because dyshidrosis appears to be more common during times of stress * Exposure to metal salts, such as chromium, cobalt and nickel — usually through cement or mechanical work * Having seasonal allergies, such as hay fever * Frequently exposing your skin to water or other wet substances
Comments:   The resulting small, fluid-filled blisters (vesicles) most commonly occur on the palms and fingers of your hands and on the soles and toes of your feet. The blisters usually last for three to four weeks. The blisters often cause intense itching. Scratching the blisters can damage the skin and, in some cases, lead to infection. Once the blisters dry, they often leave cracks and painful grooves (fissures) in your skin. Risk factors Dyshidrosis occurs twice as often in women as in men. Other risk factors include: * Stress, because dyshidrosis appears to be more common during times of stress * Exposure to metal salts, such as chromium, cobalt and nickel — usually through cement or mechanical work * Having seasonal allergies, such as hay fever * Frequently exposing your skin to water or other wet substances

 

Temovate review by 49 year old male patient

  Rating
Overall rating:  
Effectiveness:   Moderately Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   Dyshidrosis
Dosage & duration:   0.05% (dosage frequency: 2x per day) for the period of 2 weeks
Other conditions:   None
Other drugs taken:   None
  
Reported Results
Benefits:   reduced symptoms after using the cream for a total of two months.
Side effects:   There were no apparent side effect from using this treatment.
Comments:   cream applied twice per day for two weeks. one week without treatment and than two weeks on the treatment. Repeat this regiment until symptoms are reduced or disappear.

See all Temovate reviews / ratings >>

Page last updated: 2014-07-11

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014